Spyre Therapeutics to Participate in Upcoming Investor Conference
Spyre Therapeutics Files for $500M Mixed Securities Shelf
Express News | Spartan Resources Ltd Files for Mixed Shelf of up to $500 Mln - SEC Filing
Spyre Therapeutics Initiated at Outperform by Wedbush
Wedbush Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $45
Buy Recommendation for Spyre Therapeutics Based on Promising IBD Pipeline and Strong Financial Position
Analysts' Top Healthcare Picks: PMV Pharmaceuticals (PMVP), Spyre Therapeutics (SYRE)
TD Cowen Remains a Buy on Spyre Therapeutics (SYRE)
Express News | Spyre Therapeutics Q2 EPS $(0.86) Beats $(0.95) Estimate
Earnings Flash (SYRE) SPYRE THERAPEUTICS Reports Q2 Loss $-0.86
Spyre Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Express News | NewAmsterdam Pharma Announces Appointments of Mark C. Mckenna and Wouter Joustra to Its Board of Directors
Express News | Spyre Therapeutics Shares up 6.1% After Evercore ISI Initiates Coverage With Outperform Rating
Express News | Spyre Therapeutics Inc : Evercore ISI Initiates Coverage With Outperform Rating
Evercore Initiates Spyre Therapeutics(SYRE.US) With Buy Rating
Express News | Spyre Therapeutics: Spy002 Remains on Track to Begin First-in-Human Studies in H2 of 2024
Express News | Spyre to Present Interim Spy001 Data by Year-End 2024
Express News | Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of Spy001, Its Novel Half-Life Extended Anti-Α4Β7 Antibody, for the Treatment of Inflammatory Bowel Disease
Spyre Therapeutics Down Nearly 20%, on Pace for Largest Percent Decrease Since June 2023 -- Data Talk